Aug 31, 2023
Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer
Jul 31, 2023
Biomea Fusion Reports Second Quarter 2023 Financial Results and Corporate Highlights
Jul 24, 2023
BMF-219 Induces Complete Responses in Target Acute Myeloid Leukemia (AML) Patient Population
Jun 23, 2023
Biomea Fusion Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Association (ADA) 83rd Scientific Sessions; 100 mg Cohort 3 Demonstrated a 90% Response Rate and 70% Maintained or Improved Time in (Normal Glucose) Range, While Off-Treatment
Jun 20, 2023
Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes at ADA 2023
May 02, 2023
Biomea Fusion Reports First Quarter 2023 Financial Results and Corporate Highlights
May 01, 2023
Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia
Apr 19, 2023
Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes, at the ADA 83rd Scientific Sessions 2023 in June
Apr 13, 2023
Biomea Fusion To Present Two Preclinical Posters at the 114th AACR Annual Meeting
Apr 13, 2023
Biomea Fusion Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Displaying 1 - 10 of 19